- See Also
-
Links
- “Functional and Multi-Omic Aging Rejuvenation With GLP-1R Agonism”, Huang et al 2024
- “Trial of Lixisenatide in Early Parkinson’s Disease”, Meissner et al 2024
- “Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”, Frias et al 2023b
- “Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists”, Alhiary et al 2023
- “Evaluation of Out-Of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease”, Luo et al 2023
- “Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead”, Baig et al 2023
- “The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients”, Huang et al 2023
- “The Gut-Bone Axis in Diabetes”, Maagensen et al 2022
- “Targeting the GIPR for Obesity: To Agonize or Antagonize? Potential Mechanisms”, Ampbell 2012
- “Normalization of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (non-Insulin-Dependent) Diabetic Patients”, Nauck et al 1993
- “Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) Amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach”, Ørskov et al 1988
- Wikipedia
- Miscellaneous
- Link Bibliography
See Also
Links
“Functional and Multi-Omic Aging Rejuvenation With GLP-1R Agonism”, Huang et al 2024
Functional and multi-omic aging rejuvenation with GLP-1R agonism
“Trial of Lixisenatide in Early Parkinson’s Disease”, Meissner et al 2024
“Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”, Frias et al 2023b
“Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists”, Alhiary et al 2023
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
“Evaluation of Out-Of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease”, Luo et al 2023
“Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead”, Baig et al 2023
Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead:
View PDF:
“The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients”, Huang et al 2023
“The Gut-Bone Axis in Diabetes”, Maagensen et al 2022
“Targeting the GIPR for Obesity: To Agonize or Antagonize? Potential Mechanisms”, Ampbell 2012
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
